cGMP-Compliant, Validated Technology Enhances Biological Activity Enabling Clinical Delivery of Safe and Effective Cellular Therapeutics

GAITHERSBURG, Md.–MaxCyte today announces the launch of the MaxCyte® GT™ Flow Transfection System to academic and clinical investigators. The MaxCyte® GT™ Flow Transfection System is a validated platform for optimizing the biological activity of cellular therapeutic products. The system, which is supported by US FDA Master File and CE marking, enables rapid and efficient transfection of any primary cell or cell line to achieve greater than 90% cell viability. A broad range of molecules (protein, drug, plasmid, mRNA, or siRNA) or combinations thereof, at volumes up to tens of billion cells, can be processed in less than 30 minutes. The system permits rapid, automated, cGMP-compliant, closed system cell processing for both cGMP facility and point-of-care use. The MaxCyte® GT™ Flow Transfection System enables cost-effective delivery with both autologous and allogeneic cellular therapies, customized for enhanced efficacy.

“The MaxCyte® GT™ Flow Transfection System enables design and development of engineered cell products with enhanced potency and permits robust, automated, cost-effective, and regulatory-compliant manufacturing,” says Dr. Madhusudan V. Peshwa, Executive Vice President of Cellular Therapies at MaxCyte. “Such improvement in efficacy and reduction in delivery risk in the early-stages of product development significantly reduces cost and accelerates development while providing for novel Intellectual Property around engineered cell therapy and stem cell products.”

“The MaxCyte® GT™ Flow Transfection System has been validated in a marketed oncology therapy and several other cellular therapies in phase I/II clinical studies targeting oncology and regenerative medicine applications. These experiences demonstrate our technology’s ability to customize and enhance biological activity of cells and ensure robust product manufacturing,” stated Mr. Douglas A. Doerfler, Founder, CEO and President of MaxCyte. “We are excited to make available the MaxCyte® GT™ Flow Transfection System to Academic and Clinical investigators to enable the development and clinical translation of the next generation cellular therapeutics.”

Academic and Clinical investigators interested in learning more about the MaxCyte® GT™ Flow Transfection System can download a technical brochure from the following site: https://www.maxcyte.com/pdf/MaxCyte_Brochure_GT_8.5x11_FINAL.pdf.

About MaxCyte

MaxCyte is the leader in providing clinical/commercial cell modification technologies and technical expertise to enable the development of proprietary enhanced cellular therapeutics to global leaders in life sciences. MaxCyte’s unique transfection technology platform enables the discovery, development, manufacturing and delivery of innovative and important therapeutic products for a wide range of diseases. MaxCyte’s proprietary cell loading technology provides critical enablement for cell therapeutics targeting a broad range of chronic diseases by allowing the controlled modification of cell function. By providing unparalleled consistency, scalability, and loading efficiency while avoiding the inherent drawbacks of alternative methods, the MaxCyte® GT™ Flow Transfection System enables the development of proprietary enhanced therapies that cannot otherwise be commercialized. MaxCyte’s clinical-grade cell loading technology platform is supported by an FDA Master File and well validated, with multiple products enabled by the MaxCyte technology in clinical development and on market. Building on these experiences, MaxCyte also offers the MaxCyte STX™ Scalable Transfection System as a product for sale to biopharmaceutical companies involved in the burgeoning area of cell-based drug screening and small molecule drug discovery.